This suggests a new mechanism by which PD-L1 is regulated and blocking the CK2-PD-L1 pathway by inhibition of Tim-3 might be a potential anti-tumor treatment option to activate DC function [322]. This evidence concerns the gene HAVCR2 and neoplasm.